A discussion series reviewing the differences between unbranded biologics and biosimilars and an overview of payer and provider considerations for decision-making.
EP. 1: Overview and Prevalence of Biologics
Dr David Charles, MD, opens a discussion surrounding the increasing usage and unique characteristics of biologics.
EP. 2: Defining Unbranded Biologics
Distinctions between unbranded biologics, branded biologics, and biosimilars are explored by David Charles, MD.
EP. 3: Clinical Impacts of Biologics on Patient Quality of Care
Dr Charles discusses the clinical impacts that nonmedical switching of biologic treatments can have on quality of patient care.
EP. 4: Pipeline Development and Future Implications of Unbranded Biologics
Dr Charles provides his closing insights, focusing on unbranded biologics targeted for pipeline development.
EP. 5: Emphasizing Biologics Space as Payer Priority
Kareem Karara, PharmD, BCPS, CCHP continues this discussion on unbranded biologics, discussing payer priorities for treatment options.
EP. 6: Evolving Complexity of Biologics Space
Dr Karara discusses evolution of the biologics space and highlights important regulatory definitions.
EP. 7: Differentiating Between Unbranded Biologics and Biosimilars
Differences between biologics – both branded and unbranded – and biosimilars are explored by Dr Karara.
EP. 8: The Impact of Unbranded Biologics in the Evolving Treatment Landscape of Autoimmune Disease
Dr Karara provides insight into how unbranded biologics are impacting the overall treatment landscape.
EP. 9: Implications of Multiple Switching with Biologic Therapies
Study-based findings provide support for considerable implications of multiple switching between biosimilar and originator products.
EP. 10: Factors Affecting Biologics Affordability for Patient Treatment
Kareem Karara discusses several factors impacting the affordability of biologics for patient care pathways.
EP. 11: Pipeline Development Outlook and Future Implications of Unbranded Biologics and Biosimilars
With his closing thoughts, Kareem Karara looks to the potential pipeline biologic development of biosimilars and unbranded biologics.
2 Clarke Drive Cranbury, NJ 08512